1.65 USD
▲+0.01+2.48%
2026-08-03
市值
$190.82M
市盈率
—
EPS
-0.92
股息率
—
52 周区间
1.46 – 6.79
成交量
250.17K
Beta
1.48
目标价
8.00
52W 低 1.4652W 高 6.79
价格走势
公司简介
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab a...